Navigation Links
DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
Date:2/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the fourth closing in a private placement consisting of approximately 2.0 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.6 million. The total amount raised in the private placement to date is $9.5 million.

Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.  The maximum offering in the Private Placement consisted of 9,375,000 units for gross proceeds of $7.5 million.  In addition, the placement agent has been granted an over-allotment option of up to 3,125,000 units to cover over-subscriptions for additional gross proceeds of up to $2.5 million.  The over-allotment option is being exercised in part in connection with this closing.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com;   
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
2. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
3. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
6. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
7. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
11. New Avenues to Market - Research Report on Isis Pharmaceuticals, Inc., Avon Products, Inc., Elizabeth Arden, Inc., Boyd Gaming Corporation and Ameristar Casinos, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... 2019 , ... Triple W, an innovator of connected health ... will be highlighted at the Japan - U.S. Innovation Awards Symposium ... recognizes startups with Japanese founders developing exciting technologies and highly innovative business ideas ...
(Date:7/17/2019)... ... July 17, 2019 , ... As the healthcare environment ... to keep pathologists, laboratory professionals and residents on the forefront of the profession, ... care. , Renowned Speakers Covering Crucial Topics , On September 11, Her ...
(Date:7/17/2019)... ... ... Steven C. Bilt, Chief Executive Officer of Smile Brands Inc. spoke about the ... a panel discussion at Dykema’s 6th Annual Definitive Conference for Dental Service Organizations (DSOs). ... Texas. , Bilt co-founded Smile Brands Inc. in 1998 and has been instrumental at ...
Breaking Medicine Technology:
(Date:7/18/2019)... Fla. (PRWEB) , ... July 18, 2019 , ... Dr. ... recent scientific studies in order to accurately address concerns brought to him by his ... of dental floss has been brought to his attention by patients in his Clearwater, ...
(Date:7/18/2019)... ... 18, 2019 , ... Gateway Genomics , a leading developer of genomic ... “ Accurate Fetal Sex Determination from Maternal Blood at 8 Weeks Gestation ” in ... were collected from 108 women at an average gestational age of 8 weeks. Cell-free ...
(Date:7/17/2019)... , ... July 17, 2019 , ... ... leader offering fresh, insightful, honest perspectives on today’s issues affecting humanity at practical ... 12 p.m. PST on Saturday, July 20, 2019. , Guruji Mahendra Trivedi ...
(Date:7/17/2019)... Ky. (PRWEB) , ... July 17, 2019 , ... ... awarded to Eastern Kentucky University’s online Family Nurse Practitioner program. The honor is ... quality in distance education. , The Catalyst Awards honor institutions from around ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... of critical access hospitals. , The men and women included on this list ... expansions, mergers and EHR implementations as well as the construction of satellite clinics ...
Breaking Medicine News(10 mins):